1. Home
  2. HCI vs AUPH Comparison

HCI vs AUPH Comparison

Compare HCI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCI Group Inc.

HCI

HCI Group Inc.

N/A

Current Price

$156.55

Market Cap

2.3B

Sector

Finance

ML Signal

N/A

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$14.24

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HCI
AUPH
Founded
2006
1993
Country
United States
Canada
Employees
552
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
HCI
AUPH
Price
$156.55
$14.24
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$230.00
$17.25
AVG Volume (30 Days)
106.6K
1.1M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
1.03%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
$11.44
$16.53
Revenue Next Year
$7.67
$16.24
P/E Ratio
$9.97
$6.86
Revenue Growth
N/A
20.38
52 Week Low
$129.58
$6.83
52 Week High
$210.50
$16.54

Technical Indicators

Market Signals
Indicator
HCI
AUPH
Relative Strength Index (RSI) 42.13 47.76
Support Level $151.72 $13.52
Resistance Level $158.85 $15.23
Average True Range (ATR) 4.94 0.47
MACD -1.33 0.01
Stochastic Oscillator 23.02 28.32

Price Performance

Historical Comparison
HCI
AUPH

About HCI HCI Group Inc.

HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: